Videos

Conaghan discussed the potential of StEPP as a measure in clinical trials.

Cuda discussed the potential of the NIH toolbox to easily assess cognitive effects in clinical trials.

Conaghan discussed the potential of LEVI-04 for knee osteoarthritis at ACR 2025.

Cuda discussed the link between SLE disease activity and cognitive deficits,

Phase 2 trial shows ianalumab achieves sustained lupus disease control, supports steroid tapering, and increases time in remission over 1 year.

Phase 3 data show dapirolizumab pegol improved remission and disease stability in lupus; a second trial and patient-reported outcomes are now underway.

At ACR 2025, Vital discussed phase 3 data showing dapirolizumab pegol improved remission and stabilized disease activity in patients with lupus.

Jin discussed new evidence supporting the immune-modulating effects of low-dose IL-2 at ACR 2025.

Mease discussed the latest updates on bimekizumab, sonelokimab, and izokibep at ACR Convergence 2025.

Recent trial findings show Nanoencapsulated Sirolimus Plus Pegadricase can improve symptoms of uncontrolled gout.

Graf shared his excitement for a potential new first-in-class therapy for rheumatoid arthritis.

Obinutuzumab was approved earlier in October for LN under the name Gazyva.

Behrens discussed strong data supporting secukinumab's use over ustekinumab post-TNF inhibitor in PsA.

Daien shared her excitement for new data supporting fiber supplementation to improve MTX response in rheumatoid arthritis.

Conaghan discussed findings from the ENX-CL-05-001 phase 2a trial at the ACR Convergence.

Mysler emphasized the first definitive evidence informing sequencing after failing a first TNF inhibitor.

Prajapati discussed the impact of the expanded approval of guselkumab to pediatric PsO and psoriatic arthritis.

Kimura also highlighted the importance of coordinating with pediatricians.

Zangoglia shared advantages physical therapies may offer in treating people with fibromyalgia.

Kimura highlighted some of her ongoing research tackling high priority questions in JIA.

Recent phase 3 trials reveal promising results for Duravancinib in treating psoriatic arthritis, showcasing efficacy and a strong safety profile.

Tonix Pharmaceutical's therapy has a PDFUA date of August 15, 2025.

Zasocitinib recently demonstrated better ACR responses than placebo in new trial data.

Buttgereit discussed notable findings from the SELECT-GCA trial

Nowak also shared his outlook on research in myasthenia gravis in the next 5 years.

July is Juvenile Idiopathic Arthritis Month and Onel discussed complexities of transitioning care.

July is Juvenile Arthritis Month and Onel discussed complexities of transitioning care.

Mease described his real-world experience with using bimekizumab in the clinic for treating PsA and AxSpA.

Rilzabrutinib shows promising remission rates in IgG4-related disease with minimal glucocorticoid use, offering a safer oral treatment option.

New findings highlight upadacitinib's effectiveness in treating giant cell arteritis, showcasing lower infection rates and improved glucocorticoid tapering strategies.